This study focused on the tumor volume reduction rate during the THP phase (δV1) as a potential early imaging biomarker for pCR prediction and aimed to determine optimal δV1 thresholds that could stratify patients according to treatment response and inform a more precise and individualized NST strategy for HER2-positive breast cancer. Here, ERBB2 is linked to neoplasm.